Joao V. Alessi
机构：Dana-Farber Cancer Institute, Hospital Sírio-Libanês · ORCID：0000-0002-8072-5946
发表论文 810 篇 · 总被引 3360 次 · h-index 28
代表论文
- Data from Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco (2026)
- Supplementary Data1 from Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco (2026)
- Supplementary Figure 6 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors (2026)
- Supplementary Figure 3 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors (2026)
- Supplementary Table 3 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors (2026)
- Supplementary Figure 13 from Activating Point Mutations in the <i>MET</i> Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors (2026)